Thought this part of the article was interesting..
Post# of 148288
CytoDyn on April 13 appointed its Chairman, Scott A. Kelly, MD, to the additional position of Chief Medical Officer and Head of Busines Development, a move it said would accelerate evaluation of leronlimab for COVID-19 and other indications
Is this just the fact that we have a full time CMO so the FDA would take us more seriously?